Welcome to our dedicated page for Ikena Oncology news (Ticker: IKNA), a resource for investors and traders seeking the latest updates and insights on Ikena Oncology stock.
Ikena Oncology (NASDAQ: IKNA) is a clinical-stage biopharmaceutical company pioneering biomarker-driven therapies targeting cancer's molecular drivers. This page provides investors and researchers with essential updates on IKNA's pipeline progress, strategic partnerships, and scientific advancements in precision oncology.
Access real-time announcements about IKNA's programs, including developments in Hippo pathway inhibitors and RAS signaling research. Our curated news collection features earnings reports, clinical trial milestones, and corporate updates – all critical for evaluating the company's position in targeted cancer therapy.
Key content includes updates on IKNA's precision medicine approach, collaborations with industry leaders, and regulatory filings. Bookmark this page to efficiently track how the company addresses therapeutic resistance mechanisms through its innovative drug candidates.
Ikena Oncology (IKNA) received Fast Track designation from the FDA for its drug IK-930, a novel TEAD inhibitor aimed at treating unresectable NF2-deficient malignant pleural mesothelioma (MPM). This designation accelerates drug development for serious conditions and allows for increased interaction with the FDA. Earlier in 2022, IK-930 also received Orphan Drug designation, highlighting its potential for rare disorders. About 40% of mesothelioma patients are NF2-deficient, indicating a significant target market. IK-930 is currently in Phase 1 clinical trials, with encouraging preclinical data presented at the AACR 2022.
Ikena Oncology (Nasdaq: IKNA) announced its participation in two upcoming conferences: the H.C. Wainwright Global Investment Conference from May 23-26, 2022, and the Jefferies Global Healthcare Conference from June 8-10, 2022. CEO Mark Manfredi will present a corporate update at the Wainwright conference on May 25, 2022, at 11:30 a.m. ET, and participate in a fireside chat at the Jefferies Conference on June 9, 2022, at 10:00 a.m. ET. Webcasts will be available on Ikena's website.
Ikena Oncology (Nasdaq: IKNA) announced significant advancements in its clinical programs, including the progression of the IK-175 combination trial for urothelial carcinoma to Stage 2 due to tolerability and preliminary anti-tumor activity. The company has initiated its first-in-human clinical trial for IK-930, a TEAD inhibitor targeting Hippo pathway alterations. Financially, Ikena reported $212.4 million in cash and cash equivalents as of March 31, 2022, with a net loss of $16.8 million for Q1 2022, an increase from the previous year. The company expects its funds to last through mid-2024.
Seismic Therapeutic announced the appointment of Maude Tessier, PhD, as Chief Business Officer. With over 16 years of experience in biotech, Tessier previously held similar roles at Ikena Oncology (NASDAQ: IKNA), where she facilitated a $1B+ partnership with BMS and secured over $260M in capital. Her expertise in business development and strategic initiatives is expected to drive Seismic's long-term growth strategy in immunology drug development. CEO Jo Viney emphasized Tessier's role in building strategic partnerships and expanding the company’s promising pipeline.
Ikena Oncology has announced a partnership with the Vall d’Hebron Institute of Oncology (VHIO) to generate tumor and biomarker-specific data for targeted cancer therapies. This collaboration aims to enhance Ikena's understanding of the Hippo and RAS pathways, vital for developing novel cancer treatments. VHIO's comprehensive resources and expertise will support Ikena in accessing diverse patient populations and improving research on cancer biology. The partnership marks VHIO's first multidisciplinary collaboration with a biotech firm.
BOSTON, April 28, 2022 - Ikena Oncology (Nasdaq: IKNA) announced presentations at the upcoming ASCO 2022 Annual Meeting. The company will showcase two trial-in-progress posters, detailing their clinical trials for IK-930, a TEAD inhibitor, and IK-175, an AHR antagonist. Both trials target advanced solid tumors. The presentations are scheduled for June 5, 2022, during the Poster Session on Developmental Therapeutics. Abstracts will be accessible on asco.org from May 26, 2022, at 5 PM ET.
Ikena Oncology has appointed Dr. Jotin Marango as Chief Financial Officer and Head of Corporate Development, effective April 13, 2022. With nearly 15 years of experience, Dr. Marango previously served at Aptose Biosciences as CFO and Chief Business Officer. His expertise spans oncology biopharma business, finance, and corporate relations. The appointment aligns with Ikena’s strategy to advance its targeted oncology programs and strengthen investor relations. Dr. Marango holds degrees from Harvard University and Mount Sinai School of Medicine.
Ikena Oncology, Inc. (Nasdaq: IKNA) announced its 2021 financial results, raising over $140 million in an IPO and ending the year with cash reserves of $232.2 million, ensuring its runway through mid-2024. The company advanced its clinical pipeline, initiating the Phase 1 trial for its lead candidate IK-930, a TEAD inhibitor. Additionally, IK-175, an AHR antagonist, expanded its clinical cohorts. Despite a net loss of $34.1 million in 2021, improvements in cash management and pipeline expansion position Ikena favorably for upcoming milestones in 2022.
Ikena Oncology (Nasdaq: IKNA) announced its participation in the AACR 2022 Annual Meeting, highlighting its novel TEAD inhibitor, IK-930. Dr. Jeff Ecsedy will present data supporting IK-930's clinical potential on April 11, 2022, during a minisymposium on experimental and molecular cancer therapeutics. The meeting will take place from April 8-13, 2022, in New Orleans. IK-930 targets the Hippo signaling pathway, aiming to treat cancers with mutations affecting this pathway, with ongoing Phase 1 trials for advanced solid tumors.
Ikena Oncology (Nasdaq: IKNA) will participate in the Targeted Oncology Panel at the Cowen & Co 42nd Annual Health Care Conference scheduled for March 7-9, 2022.
CEO Mark Manfredi will speak on March 8 at 9:10 a.m. ET.
The event will be streamed live and archived for 30 days. Ikena focuses on developing therapies targeting cancer pathways, with its lead program IK-930 being a TEAD inhibitor for the Hippo pathway, among others.
For more details, visit www.ikenaoncology.com.
FAQ
What is the current stock price of Ikena Oncology (IKNA)?
What is the market cap of Ikena Oncology (IKNA)?
